Market Update (NYSE:LLY): Lilly Announces Diabetes Commercial Update Investor Call

[PR Newswire] – INDIANAPOLIS, June 1, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the company’s diabetes … Read more on this. Eli Lilly and Company (LLY) , valued at $79.08B, started trading this morning at $74.90. Looking at the stock, its one day range is $74.68 to $75.44 with its 52-week range being $67.88 to $92.85. Priced at 21.08x this year’s forecasted earnings, LLY shares are relatively expensive compared to the industry’s -0.14x forward p/e ratio. And for dividend hunters, the company pays shareholders $2.04 per share annually in dividends, yielding 2.72%. According to a consensus of 17 analysts, the earnings estimate of $0.85 per share would be $0.05 worse than the year-ago quarter and a $0.02 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $3.56 is a $0.13 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $5.14 Billion. If realized, that would be a 3.21% increase over the year-ago quarter. More recently, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. The average price target for LLY shares by the analysts covering it is $95.71, which is 27.78% above where the stock opened. See more in (NYSE:LLY) Similar Articles: Market Update (NYSE:LLY): Lilly Announces Webcast to Discuss Abemaciclib Data Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation